Therapy for myeloproliferative neoplasms: when, which agent, and how?
HL Geyer, RA Mesa - Blood, The Journal of the American …, 2014 - ashpublications.org
Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia,
and myelofibrosis (MF)(both primary and secondary), are recognized for their burdensome …
and myelofibrosis (MF)(both primary and secondary), are recognized for their burdensome …
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the E uropean U nion
O Moulard, J Mehta, J Fryzek, R Olivares… - European journal of …, 2014 - Wiley Online Library
Background Primary myelofibrosis (PMF), essential thrombocythemia (ET), and
polycythemia vera (PV) are BCR ABL‐negative myeloproliferative neoplasms (MPN) …
polycythemia vera (PV) are BCR ABL‐negative myeloproliferative neoplasms (MPN) …
Epidemiology of myeloproliferative neoplasms in the United States
J Mehta, H Wang, SU Iqbal, R Mesa - Leukemia & lymphoma, 2014 - Taylor & Francis
Abstract Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are
three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs) …
three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs) …
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
S Verstovsek, F Passamonti, A Rambaldi, G Barosi… - Cancer, 2014 - Wiley Online Library
BACKGROUND Polycythemia vera (PV) is a myeloproliferative neoplasm associated with
somatic gain‐of‐function mutations of Janus kinase‐2 (JAK2). Therapeutic options are …
somatic gain‐of‐function mutations of Janus kinase‐2 (JAK2). Therapeutic options are …
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal
expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or …
expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or …
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
P Guglielmelli, F Biamonte, G Rotunno… - Blood, The Journal …, 2014 - ashpublications.org
The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and
symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective …
symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective …
How I treat polycythemia vera
AM Vannucchi - Blood, The Journal of the American Society of …, 2014 - ashpublications.org
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm associated with JAK2
mutations (V617F or exon 12) in almost all cases. The World Health Organization has …
mutations (V617F or exon 12) in almost all cases. The World Health Organization has …
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients
HL Geyer, RM Scherber, AC Dueck… - Blood, The Journal …, 2014 - ashpublications.org
Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among
patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered …
patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered …
[HTML][HTML] Diagnosis and management of polycythemia vera: proceedings from a multidisciplinary roundtable
LA Raedler - American health & drug benefits, 2014 - ncbi.nlm.nih.gov
ic events. 14 These major events (Table 1) are the primary cause of mortality in patients with
PV, accounting for 45% of all deaths. 15 Other major causes of death among individuals with …
PV, accounting for 45% of all deaths. 15 Other major causes of death among individuals with …
Use of the functional assessment of cancer therapy− anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia
Background Anemia is common in myeloproliferative neoplasm (MPN)− associated
myelofibrosis. The Functional Assessment of Cancer Therapy (FACT) measurement system …
myelofibrosis. The Functional Assessment of Cancer Therapy (FACT) measurement system …